- Home
- ABEV vs TAK Comparison
ABEV vs TAK Comparison
Compare ABEV & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABEV | TAK |
|---|---|---|
| Founded | 1885 | 1781 |
| Country | Brazil | Japan |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.4B | 43.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ABEV | TAK |
|---|---|---|
| Price | $2.79 | $16.27 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.53 | N/A |
| AVG Volume (30 Days) | ★ 22.8M | 2.6M |
| Earning Date | 02-12-2026 | 01-29-2026 |
| Dividend Yield | ★ 6.90% | 3.24% |
| EPS Growth | ★ 15.78 | N/A |
| EPS | ★ 0.19 | 0.14 |
| Revenue | $16,975,691,794.00 | ★ $29,846,840,032.00 |
| Revenue This Year | $3.57 | N/A |
| Revenue Next Year | $4.38 | $0.47 |
| P/E Ratio | ★ $14.59 | $229.14 |
| Revenue Growth | ★ 9.79 | N/A |
| 52 Week Low | $1.79 | $12.80 |
| 52 Week High | $2.81 | $16.48 |
Technical Indicators
Market Signals| Indicator | ABEV | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 75.16 | 64.05 |
| Support Level | $2.56 | $15.78 |
| Resistance Level | $2.61 | $16.25 |
| Average True Range (ATR) | 0.05 | 0.24 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 95.83 | 79.50 |
Price Performance
Historical ComparisonAbout ABEV Ambev S.A.
Ambev is the largest brewer in Latin America and the Caribbean and is Anheuser-Busch InBev's subsidiary in the region. It produces, distributes, and sells beer and PepsiCo products in Brazil and other Latin American countries and owns Argentina's largest brewer, Quinsa. Ambev was formed in 1999 through the merger of Brazil's two largest beverage companies, Brahma and Antarctica. In 2004, Ambev combined with Canadian brewer Labatt, giving AB InBev a controlling interest of 62%.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.